天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (11): 1367-1370.doi: 10.11958/20160528

• 临床研究 • 上一篇    下一篇

miR-486、 miR-499 在肺癌患者血浆中的表达及临床价值

杨阳 1， 2， 杨晴 3， 贾友超 2， 李小芳 2， 杨华 2， 张倩 2， 彭鑫宇 4， 臧爱民 2△   

  1. 1 河北大学 （邮编 071002）； 2 河北省放化疗机制与规程重点实验室， 河北大学附属医院肿瘤内科； 3 输血科， 4 肝胆外科
  • 收稿日期:2016-06-12 修回日期:2016-09-09 出版日期:2016-11-15 发布日期:2016-11-15
  • 通讯作者: △通讯作者 E-mail:booszam@sina.com E-mail:499403762@qq.com
  • 作者简介:杨阳 （1985）， 男， 硕士在读， 主要从事肺癌分子生物学研究
  • 基金资助:
    2015 年河北省政府资助临床医学优秀人才项目 （361007）

The expression and clinical significance of plasma miR-486 and miR-499 in patients with lung cancer

YANG Yang1, 2, YANG Qing3, JIA Youchao2, LI Xiaofang2, YANG Hua2, ZHANG Qian2, PENG Xinyu4, ZANG Aimin2△   

  1. 1 Hebei University, Baoding 071002, China; 2 Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, the Affiliated Hospital of Hebei University; 3 Department of Blood Transfusion, 4 Department of Hepatobiliary Surgery, the Affiliated Hospital of Hebei University
  • Received:2016-06-12 Revised:2016-09-09 Published:2016-11-15 Online:2016-11-15
  • Contact: △Corresponding Author E-mail:booszam@sina.com E-mail:499403762@qq.com

PDF (PC)

3807

摘要： 目的 探讨 miR-486 和 miR-499 在肺癌患者血浆中的表达及临床意义， 分析其在非小细胞肺癌 （NSCLC）和小细胞肺癌（SCLC）中表达的差异。方法 收集 35 例肺癌患者（其中 NSCLC 组 21 例， SCLC 组 14 例）及 30 例健康者（对照组）血样标本， 运用 qPCR 的方法测定各组血浆 miR-486、 miR-499 的表达量， 分析 NSCLC 和 SCLC 患者血浆中 miR-486 和 miR-499 的表达量与各临床特征的关系。对所有入组者血浆 miRNA 的相对表达量进行 ROC 曲线分析， 计算曲线下面积（AUC）、 最佳临界值及其敏感度和特异度。结果 NSCLC 和 SCLC 组中血浆 miR-486、 miR-499 的相对表达量均低于对照组（P＜0.05）。NSCLC 组血浆 miR-486 在不同临床特征患者间表达差异均无统计学意义； 而 TNM 分期越晚、 分化程度越低， miR-499 表达越低（P＜0.05）。SCLC 组分期越晚， miR-486 表达越低；而 miR-499 在不同临床特征患者间表达差异均无统计学意义。miR-486 诊断肺癌的 AUC 为 0.83（95%CI 为 0.73~ 0.93）， 敏感度和特异度分别为 90.0%和 68.6%， 最佳诊断界值为 1.02； miR-499 诊断肺癌的 AUC 为 0.75（95%CI 为 0.62~0.88）， 敏感度和特异度分别为 60.0%和 94.3%， 对肺癌的最佳诊断界值为 0.32。结论 血浆 miR-486、 miR-499 在肺癌患者中表达下调， 可能预示预后不良， 有望作为肺癌潜在筛查及预后的指标。

关键词: 癌, 非小细胞肺, 微 RNAs, 血浆, 敏感性与特异性, 诊断, 鉴别, miR-486, miR-499

Abstract: Objective To explore the expression levels of miR- 486 and miR- 499 in the plasma of lung cancer patients, and analyze their expression differences in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Methods Blood samples were collected in 35 patients with lung cancer (21 NSCLC and 14 SCLC) and 30 healthy persons (control group). The real-time quantitative PCR was used to detect the expression levels of plasma miR-486 and miR-499 in two groups. The plasma levels of miRNA- 486 and miRNA- 499 and their correlation with various clinical features in NSCLC and SCLC patients were analyzed. The receiver operating characteristic curves（ROC）of miRNA expressions were analyzed. The area under a curve（AUC） , threshold and the sensitivity and specificity were calculated. Results The expression levels of miR-486 and miR-499 were significantly lower in NSCLC and SCLC groups than those of the control group（P<0.05). There were no significant differences in the expression of miR- 486 between different clinical features in NSCLC group. For the late cancer TNM staging, the tumor differentiation was lower, and the miR-499 expression level was lower (P<0.05). In SCLC group, for the late cancer staging, there was a lower expression level of miR- 486. There were no significant differences in the expressions of miR- 499 between different clinical features. The miRNA- 486 AUC in the diagnosis of lung cancer was 0.83(95% CI: 0.73- 0.93), the sensitivity and specialty rates were 90.0% and 68.6% respectively, and the best diagnostic value was 1.02. The miRNA-499 AUC in the diagnosis of lung cancer was 0.75 (95% CI: 0.62- 0.88), the sensitivity and specialty rates were 60.0% and 94.3% respectively, and the best diagnostic boundary value was 0.18 for lung cancer. Conclusion The plasma expression levels of miR-499 and miR-486 are down-regulated in lung cancer patients, which suggest a poor prognosis and can be used as potential screening and prognostic indicators for lung cancer.

Key words: carcinoma, non-small-cell lung, microRNAs, plasma, sensitivity and specificity, diagnosis, differential, miR-486, miR-499